Azura Ophthalmics nets $20m

Azura Ophthalmics Ltd, an Israeli developer of therapies for Meibomian gland dysfunction and related eye diseases, has raised $20 million in financing.

Azura Ophthalmics Ltd, an Israeli developer of therapies for Meibomian gland dysfunction and related eye diseases, has raised $20 million in financing. The investors included OrbiMed, TPG Biotech, Brandon Capital’s Medical Research Commercialization Fund and Ganot Capital.

Source: Press Release